Despite breakthroughs in interventional, pharmacological, and surgical therapy, organ failure remains the top cause of death worldwide. Since then, beyond human memory, bioartificial organ manufacturing has been a long-term goal. Man-made organs may, in the not-too-distant future, save the lives of people whose kidneys, pancreas, or lungs are failing. The design, modification, growth, and maintenance of living tissues implanted in natural or synthetic scaffolds to enable them to execute complicated biochemical activities, such as adaptive regulation and the replacement of regular living tissues, are all part of bioartificial organs. Healthy human cells (produced from organ tissue discarded during surgery) and biomaterials are used to construct bioartificial organs. A bioartificial kidney, for example, is constructed from kidney cells that have been cleverly linked to a ′membrane, ′ a porous capillary built from artificial polymer fibre. When human plasma is pushed via this tube, it reaches the kidney cells, which detect and eliminate toxins. In vitro, this bioartificial kidney can filter and cleanse blood, simulating the function of a real, healthy kidney. Future research will move away from the trial-and-error approach to implant optimization and toward the rational manufacturing of precisely formed nano biological devices.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States